Where does Calithera Biosciences, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Calithera Biosciences, Inc. ranks #10,569 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Calithera Biosciences, Inc. hold?

Calithera Biosciences, Inc. holds 29 US utility patents granted between 2017 and 2022, spanning 13 technology areas.

What is Calithera Biosciences, Inc.'s Innovation Score?

Calithera Biosciences, Inc. has an Innovation Score of 40.4 out of 100 (top 36% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Calithera Biosciences, Inc.'s patent grant rate increasing or decreasing?

Calithera Biosciences, Inc.'s recent grant velocity is +42% compared to the prior five-year period (grant years, not application filing dates). The company is maintaining or growing its granted-patent output.

What does claim depth mean for Calithera Biosciences, Inc.'s patents?

Calithera Biosciences, Inc.'s patents average 30.0 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Calithera Biosciences, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Calithera Biosciences, Inc.

Q: What technology areas does Calithera Biosciences, Inc. focus on?

Calithera Biosciences, Inc.'s top technology area is A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS) with 23 patents. Grants appear in 13 CPC subclasses total.

USPTO PatentsView assignee record - 29 granted patents across 13 technology areas, recorded in grant years 2017–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).

Compiled by PlainPatent · May 15, 2026

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Calithera ranks #10,569 of 50,000 tracked US assignees by granted-patent volume, with 29 patents across 13 technology areas.

#10,569
of 50,000 US assignees by volume: Top 36%
by Innovation Score (40.4/100): 30.0
avg claims per patent: +42%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R10569 · US Corporation #10,569 · 29 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-DENSE · TYPE-USCORP · VEL-UP · BOOK-FULL

GRANTS-SMALL 29 grants
UPPER-Q #10,569/50,000
PHOTO-FINISH C3 Nano
CPC-FOCUS A61P · 13 areas
INNOV-PAR 40.4/100
CLAIMS-DENSE 30.0 claims/avg
TYPE-USCORP US Corporation
VEL-UP +42% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: C3 Nano, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Calithera Biosciences · this assignee

40
Fluid Equipment Deve… · near

40
GE Healthcare AS · near

40
Mesoblast Internatio… · near

40
Personics Holdings · near

40
3D Lighting Innovati… · lowest

7

What this shows Calithera Biosciences, Inc. stamps GRANTS-SMALL, UPPER-Q, PHOTO-FINISH, CPC-FOCUS, INNOV-PAR, CLAIMS-DENSE, TYPE-USCORP, VEL-UP, BOOK-FULL. Volume places it #10,569 of 50,000; Innovation Score 40.4/100 sits in the top 36% of the PatentsView-derived corpus. Closest grant-volume peer on this plate is C3 Nano, Inc. (±0 grants).

Portfolio overview

Calithera Biosciences, Inc. has been granted 29 US utility patents between 2017 and 2022, placing Calithera Biosciences, Inc. at #10,569 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 30.0 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a US Corporation, Calithera Biosciences, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Calithera sits between C.n.r.s. (29 patents, rank #10,566) and China Communication Technology Co., Ltd. (29 patents, rank #10,574) - the closest US assignees by grant volume. The composite Innovation Score of 40.4/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 17 grants, compared with 12 in the 2015–2019 window, a +42% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The US Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Calithera Biosciences, Inc.'s 30.0 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 13 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

C N R S

29
C3 Nano

29
C4 Therapeutics

29
Calgon Carbon

29
Cbrite

29
Celltrion

29
Centre LEON Berard

29
China Communicati…

29
Calithera Bioscie… ◀

29

What this shows Calithera holds 29 patents at rank #10,570, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Calithera

By rank, the assignees closest to #10,570 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Calithera's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Calithera, neither rank-band nor same-CPC leaders (those blocks stay above).

Similar innovation score

Nearest assignees by Innovation Score (40 here).

Fluid Equipment Development Company, Llc 40 Personics Holdings, Llc 40 Mesoblast International Sàrl 40 GE Healthcare AS 40

Calithera's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

40 Top 36% higher than 64% of 50,000 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2017–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2017–2019 baseline. Full figures in the table below.

View data table

Calithera Biosciences, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2017	1	3.4%
2018	2	6.9%
2019	9	31.0%
2020	6	20.7%
2021	8	27.6%
2022	3	10.3%

Which technologies does Calithera Biosciences, Inc. patent most?

A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 23

A61K - PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES 20

C07K - PEPTIDES 10

C07D - HETEROCYCLIC COMPOUNDS 10

C07F - ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM 8

C07H - SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 5

C07B - GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR 5

G01N - INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES 3

C07C - ACYCLIC OR CARBOCYCLIC COMPOUNDS 3

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY 2

C12Q - MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS ; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES 1

C12N - MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA 1

A61B - DIAGNOSIS; SURGERY; IDENTIFICATION 1

Top 13 of 13 technology areas

Where it ranks

Overall rank by patents

#10,569

of 50,000 tracked assignees

Innovation Score

40.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.